Objective To invesligale the efficacy and lolerance of posloperalive concurrent chemoradiothera-py ( RCT) and chemotherapy ( CT) for gaslric cancer. Methods The 76 palienls who met the following enrolled cri-teria were included in the study: underwent curalive gaslreclomy and D2 lymphadeneclomy , palhologically slaged as Ⅱ -Ⅳ- 31 cases were assigned to concurrenl chemoradiotherapy group and 45 cases were in chemotherapy group. Then, 2 or 3 — year survival rale and loxicily of the two groups were evaluated. Results The 2 — year survival rales for RCT and CT groups were 85. 5% and 72. 3% respectively, 3 — year survival rales for RCT and CT groups were 69. 2% and 40% ( P = 0. 045) respectively. The 2 — year recurrence-free survival rales( RFS) for RCT and CT groups were 74. 7% and 48. 6% respectively, 3 — year recurrence-free survival rales for RCT and CT groups were 49. 8% and 30. 1% ( P = 0. 041) respectively. The incidence of grade 3 hemalological toxicily was20. 7% vsl7. 1% ( P =0. 373) , and gastrointestinal toxicily was93. 1 % vs 63. 4% ( P = 0. 034) . Conclusions The chemotherapy combined with con-formal intensity-modulated radiotherapy can improve survival rale and their prognosis.%目的 比较局部晚期胃癌根治术后同步放化疗(RCT)与单纯化疗(CT)的疗效及不良反应.方法 对76例接受胃癌根治术(R0切除,D2淋巴结清扫)、病理诊断为Ⅱ-Ⅳ期的患者的预后进行分析,其中31例接受术后放化疗,45例接受术后化疗,评价两组的2、3年生存率,无复发生存率及治疗期间的毒性反应.结果 RCT组和CT组的2年生存率分别为85.5%和72.3%,3年生存率分别为69.2%和40%(P=0.045);2年无复发生存率分别为74.7%和48.6%,3年无复发生存率分别为49.8%和30.1%(P=0.041).3级以上血液毒性发生率分别为20.7%和17.1%(P=0.373),胃肠道反应发生率为93.1%和63.4%(P=0.034).结论 局部晚期胃癌根治术后同步放化疗可以提高生存率及无复发生存率,不良反应可耐受.
展开▼
